Large Cap / Mid Cap / Small Cap / Mutual Funds / Healthcare Equipment & Services / Pharmaceuticals, Biotechnology & Life Sciences
Health Care Stocks Poised for a Recovery
Want to know what George Putnam is recommending to readers of his Turnaround Letter? The articles previewed below offer you a sneak peak of the quality content and sound investment guidance you can trust. To view his most recent recommendations click here.
Many healthcare stocks have been on a rollercoaster ride over the last few years, buffeted by both positive and negative forces. Among the positive forces are long-term demographic trends and advancements in medical technology. Some of the most negative forces emanate from Washington, including the complexities of ObamaCare and the possibility of cuts to Medicare and Medicaid.
The stocks named in the subscriber-restricted article represent a diverse group of companies in the healthcare area. Most of them have been riding the rollercoaster downwards for a while, but all of them have the potential to bottom out and begin to climb again in the coming months.
George Putnam's March 2013 Turnaround Letter article hand picks ten diverse healthcare stocks with potential to bottom out and—most importantly—begin improving stock performance in the coming months.
Read your free preview of The Turnaround Letter's most recent recommendations now!
Identify & Profit from Distressed Investing
Turnaround Investing Blog
Amazon joined Apple in reaching a $1 trillion market capitalization. $1 trillion is about the same as the total value of New York City property and the total value of loans at JP Morgan, the nation’s largest bank in terms of assets. Jeff Bezos’ $160 billion stake would place him (personally) as the #33 largest company in the S&P 500 in terms of market cap, next to Coca-Cola, Disney and Netflix. We aren’t bold enough to predict whether the shares will continue upwards or if they are in a bubble reaching maximum inflation. Setting aside for a moment their investment prospects, let’s admire the truly remarkable milestone that these two companies have reached.
EV/EBITDA: What Is It & Why Are We Using It More?
In reading recent editions of The Turnaround Letter, you have probably noticed that we are increasingly using EV/EBITDA as a valuation measure, rather than the better-known price/earnings multiple. We thought it might be useful to describe this measure and why we like it.
Turnaround Letter Stock Pick Named Top Performer of 2017
What Last Year's Top Stock Pickers Are Buying in 2018
This Forbes write-up follows up on the recent Top Stock Tips report--naming The Turnaround Letter's Crocs recommendation the top performer of 2017: With 90% gains, CROX beat out 100 other investment ideas included in the report; and the stock continues to have value investing appeal, according to Putnam.
George notes, "We see additional upside for the stock in 2018 as management's efforts continue to bear fruit, though the gains will likely be more muted than we saw in 2017."
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.